HRP20200060T1 - Nova uporaba - Google Patents
Nova uporaba Download PDFInfo
- Publication number
- HRP20200060T1 HRP20200060T1 HRP20200060TT HRP20200060T HRP20200060T1 HR P20200060 T1 HRP20200060 T1 HR P20200060T1 HR P20200060T T HRP20200060T T HR P20200060TT HR P20200060 T HRP20200060 T HR P20200060T HR P20200060 T1 HRP20200060 T1 HR P20200060T1
- Authority
- HR
- Croatia
- Prior art keywords
- medicine
- use according
- reducing
- dose
- heart failure
- Prior art date
Links
- 239000003814 drug Substances 0.000 claims 37
- 229940079593 drug Drugs 0.000 claims 27
- 239000005541 ACE inhibitor Substances 0.000 claims 10
- 206010019280 Heart failures Diseases 0.000 claims 10
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 10
- 108010061435 Enalapril Proteins 0.000 claims 8
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 8
- 229960000873 enalapril Drugs 0.000 claims 8
- 230000002526 effect on cardiovascular system Effects 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 3
- 102400001263 NT-proBNP Human genes 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 206010071436 Systolic dysfunction Diseases 0.000 claims 2
- 239000002170 aldosterone antagonist Substances 0.000 claims 2
- 229940083712 aldosterone antagonist Drugs 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 2
- 229960004699 valsartan Drugs 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 claims 1
- 229960003953 sacubitril Drugs 0.000 claims 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Claims (23)
1. Lijek, naznačen time, što sadrži
a) terapeutski učinkovitu količinu spoja trinatrijevog [3-((1S,3R)-1-bifenil-4-ilmetil-3-etoksikarbonil-1-butilkarbamoil)propionat-(S)-3'-metil-2'-(pentanoil{2"-(tetrazol-5-ilat)bifenil-4'-ilmetil}amino)butirat] hemipentahidrata (LCZ696)
ili
b) kombinaciju koja sadrži terapeutski učinkovitu količinu u molarnom omjeru 1:1 pojedinačnih spojeva
(i) valsartana ili njegove farmaceutski prihvatljive soli; i
(ii) sakubitrila ili njegove farmaceutski prihvatljive soli,
za uporabu u smanjivanju stope rizika od kardiovaskularne smrti i/ili hospitalizacija zbog zatajenja srca kod ljudskog pacijenta koji pati od kroničnog zatajenja srca klasificiranog kao razred NYHA II, III ili IV te sistoličke disfunkcije.
2. Lijek za uporabu prema patentnom zahtjevu 1, naznačen time, što se pokazalo da je lijek statistički superiorniji u smanjenju stope kardiovaskularne smrti i/ili hospitalizacija zbog zatajenja srca, izraženo kao najmanje 20% stopa smanjenja rizika u odnosu na ACE inhibitor enalapril koji se primjenjuju dva puta dnevno u dozi od 10 mg svaki puta.
3. Lijek za uporabu prema patentnom zahtjevu 2, naznačen time, što se pokazalo da je lijek statistički superiorniji u smanjenju stope kardiovaskularne smrti, izraženo kao najmanje 20% stopa smanjenja rizika u odnosu na ACE inhibitor enalapril koji se primjenjuju dva puta dnevno u dozi od 10 mg svaki puta.
4. Lijek za uporabu prema patentnom zahtjevu 2, naznačen time, što se pokazalo da je lijek statistički superiorniji u smanjenju stope hospitalizacija zbog zatajenja srca, izraženo kao najmanje 20% stopa smanjenja rizika u odnosu na ACE inhibitor enalapril koji se primjenjuju dva puta dnevno u dozi od 10 mg svaki puta.
5. Lijek za uporabu prema patentnom zahtjevu 4, naznačen time, što se pokazalo da je lijek statistički superiorniji u smanjenju stope prve hospitalizacije zbog pogoršanja zatajenja srca, izraženo kao najmanje 20% stopa smanjenja rizika u odnosu na ACE inhibitor enalapril koji se primjenjuju dva puta dnevno u dozi od 10 mg svaki puta.
6. Lijek za uporabu prema patentnom zahtjevu 1, naznačen time, što je za uporabu u smanjivanju stope rizika od kardiovaskularne smrti.
7. Lijek za uporabu prema patentnom zahtjevu 1, naznačen time, što je za uporabu u smanjivanju stope rizika od hospitalizacija zbog zatajenja srca.
8. Lijek za uporabu prema patentnom zahtjevu 7, naznačen time, što je za uporabu u smanjivanju stope rizika od prve hospitalizacije zbog pogoršanja zatajenja srca.
9. Lijek za uporabu prema patentnom zahtjevu 1, naznačen time, što je za uporabu u smanjivanju stope rizika od kardiovaskularne smrti i hospitalizacija zbog zatajenja srca.
10. Lijek za uporabu prema patentnom zahtjevu 1, naznačen time, što je lijek za smanjivanje rizika od kardiovaskularne smrti i/ili hospitalizacija zbog zatajenja srca za iznos od najmanje 20% u odnosu na ACE inhibitor enalapril koji se primjenjuju dva puta dnevno u dozi od 10 mg svaki puta, kod ljudskog pacijenta koji pati od kroničnog zatajenja srca klasificiranog kao razred NYHA II, III ili IV te sistoličke disfunkcije.
11. Lijek za uporabu prema patentnom zahtjevu 10, naznačen time, što je lijek za smanjivanje rizika od kardiovaskularne smrti za iznos od najmanje 20% u odnosu na ACE inhibitor enalapril koji se primjenjuju dva puta dnevno u dozi od 10 mg svaki puta.
12. Lijek za uporabu prema patentnom zahtjevu 10, naznačen time, što je lijek za smanjivanje rizika od hospitalizacija zbog zatajenja srca za iznos od najmanje 20% u odnosu na ACE inhibitor enalapril koji se primjenjuju dva puta dnevno u dozi od 10 mg svaki puta.
13. Lijek za uporabu prema patentnom zahtjevu 12, naznačen time, što je lijek za smanjivanje rizika od prve hospitalizacije zbog pogoršanja zatajenja srca za najmanje 20% u odnosu na ACE inhibitor enalapril koji se primjenjuju dva puta dnevno u dozi od 10 mg svaki puta.
14. Lijek za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 13, naznačen time, što pacijent ima najmanje jednu od sljedećih dodatnih karakteristika
i) povišenu razinu BNP u plazmi ili NT-proBNP, poželjno razinu BNP ≥100 pg/mL u plazmi (ili NT-proBNP ≥400 pg/mL), poželjnije razinu BNP ≥150 pg/mL u plazmi ili NT-proBNP ≥600 pg/mL, i
ii) smanjenu frakciju ejekcije lijeve klijetke (LVEF) od ≤40%.
15. Lijek za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 14, naznačen time, što pacijent ima smanjenu frakciju ejekcije lijeve klijetke (LVEF) od ≤35%.
16. Lijek za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 15, naznačen time, što pacijent prima osnovni tretman sa stabilnom dozom beta blokatora, antagonistima aldosterona i/ili diuretikom.
17. Lijek za uporabu prema patentnom zahtjevu 16, naznačen time, što pacijent prima osnovni tretman sa stabilnom dozom beta blokatora i po izboru antagonistom aldosterona.
18. Lijek za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 17, naznačen time, što pacijent, prije primanja lijeka, mora biti na stabilnoj dozi blokatora receptora angiotenzina (ARB) ili ACE inhibitora.
19. Lijek za uporabu prema patentnom zahtjevu 18, naznačen time, što pacijent mora prestati uzimati blokator receptora angiotenzina (ARB) ili ACE inhibitor najmanje 24 sata, poželjno 36 sati, prije uzimanja lijeka.
20. Lijek za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 19, naznačen time, što time što lijek sadrži LCZ696 i treba se davati oralno u dnevnoj dozi koja može doseći 400 mg uzimanjem u jednom ili više odvojenih unosa.
21. Lijek za uporabu prema patentnom zahtjevu 20, naznačen time, što se lijek treba davati oralno u dnevnoj dozi koja može doseći 400 mg uzimanjem u dva odvojena unosa (b.i.d.).
22. Lijek za uporabu prema patentnom zahtjevu 20 ili 21, naznačen time, što lijek sadrži LCZ696 i treba se davati oralno u početnoj dozi od 100 mg b.i.d. u trajanju od jednog do dva tjedna te nakon toga titriranjem do 200 mg b.i.d.
23. Lijek za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 19, naznačen time, što lijek obuhvaća kombinaciju koja sadrži terapeutski učinkovitu količinu u molarnom omjeru 1:1 pojedinačnih spojeva
(i) Yvalsartana ili njegove farmaceutski prihvatljive soli; i
(ii) Ysakubitrila ili njegove farmaceutski prihvatljive soli,
i pritom se kombinacija treba davati oralno u dva odvojena unosa (b.i.d.) dnevno, gdje svako uzimanje sadrži 103 mg valsartana, ili njegove farmaceutski prihvatljive soli, te 97 mg sakubitrila, ili njegove farmaceutski prihvatljive soli, po jedinici doziranja.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2013/056680 WO2015030711A1 (en) | 2013-08-26 | 2013-08-26 | New use |
| US201461972933P | 2014-03-31 | 2014-03-31 | |
| EP14761702.1A EP3038654B1 (en) | 2013-08-26 | 2014-08-26 | New use |
| PCT/IB2014/064074 WO2015028941A1 (en) | 2013-08-26 | 2014-08-26 | New use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200060T1 true HRP20200060T1 (hr) | 2020-04-03 |
Family
ID=51494327
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240034TT HRP20240034T1 (hr) | 2013-08-26 | 2014-08-26 | Liječenje kardiovaskularnih bolesti |
| HRP20200060TT HRP20200060T1 (hr) | 2013-08-26 | 2020-01-16 | Nova uporaba |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240034TT HRP20240034T1 (hr) | 2013-08-26 | 2014-08-26 | Liječenje kardiovaskularnih bolesti |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20160213646A1 (hr) |
| EP (3) | EP3626270B1 (hr) |
| JP (1) | JP6097888B2 (hr) |
| CY (1) | CY1122531T1 (hr) |
| DK (2) | DK3626270T3 (hr) |
| ES (2) | ES2968541T3 (hr) |
| FI (1) | FI3626270T3 (hr) |
| HR (2) | HRP20240034T1 (hr) |
| HU (2) | HUE064634T2 (hr) |
| LT (2) | LT3038654T (hr) |
| PL (2) | PL3038654T3 (hr) |
| PT (2) | PT3038654T (hr) |
| RS (2) | RS59816B1 (hr) |
| SI (2) | SI3626270T1 (hr) |
| WO (1) | WO2015028941A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016125123A1 (en) * | 2015-02-06 | 2016-08-11 | Mylan Laboratories Limited | Amorphous trisodium sacubitril valsartan and a process for the preparation thereof |
| US20180140579A1 (en) * | 2015-05-29 | 2018-05-24 | Novartis Ag | Sacubitril and valsartan for treating metabolic disease |
| CN106309388A (zh) * | 2015-06-30 | 2017-01-11 | 深圳信立泰药业股份有限公司 | 一种用于心衰治疗的药物组合物及其制备方法 |
| WO2017036420A1 (zh) * | 2015-09-06 | 2017-03-09 | 常州方楠医药技术有限公司 | 含沙库比曲和缬沙坦的药用组合物及其制备方法 |
| CN107510653A (zh) * | 2016-06-17 | 2017-12-26 | 常州爱诺新睿医药技术有限公司 | 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法 |
| CN106491600A (zh) * | 2015-09-06 | 2017-03-15 | 常州方楠医药技术有限公司 | 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法 |
| WO2017042700A1 (en) * | 2015-09-07 | 2017-03-16 | Sun Pharmaceutical Industries Limited | Solid forms of valsartan and sacubitril |
| WO2017063581A1 (zh) * | 2015-10-16 | 2017-04-20 | 深圳信立泰药业股份有限公司 | 一种用于心血管疾病治疗的口服制剂及其制备方法 |
| CN105330609B (zh) * | 2015-12-07 | 2017-12-22 | 南京正大天晴制药有限公司 | 一种制备lcz696的方法 |
| US20190054069A1 (en) | 2016-02-03 | 2019-02-21 | Novartis Ag | New use of a combination of sacubitril and valsartan |
| CN106176681A (zh) * | 2016-08-25 | 2016-12-07 | 泰力特医药（湖北）有限公司 | 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法 |
| US11382866B2 (en) | 2017-07-06 | 2022-07-12 | Mankind Pharma Ltd. | Fixed dose pharmaceutical composition of valsartan and sacubitril |
| US20210177803A1 (en) | 2018-08-23 | 2021-06-17 | Novartis Ag | New pharmaceutical use for the treatment of heart failure |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| WO2021052441A1 (zh) * | 2019-09-20 | 2021-03-25 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0443983T3 (da) | 1990-02-19 | 1996-03-18 | Ciba Geigy Ag | Acrylforbindelser |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| IL130599A0 (en) * | 1997-01-10 | 2000-06-01 | Merck & Co Inc | Use of angiotensin II antagonists to treat symptomatic heart failure |
| CN1615134A (zh) | 2002-01-17 | 2005-05-11 | 诺瓦提斯公司 | 含有缬沙坦和nep抑制剂的药物组合物 |
| MXPA05012299A (es) * | 2003-05-16 | 2006-01-30 | Novartis Ag | Composicion farmaceutica que comprende valsartan. |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| ES2536514T3 (es) | 2007-11-06 | 2015-05-26 | Novartis Ag | Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP) |
| HUE024872T2 (en) | 2008-11-22 | 2016-02-29 | Hoffmann La Roche | Use of anti-vegf antibody in combination with chemotherapy to treat breast cancer |
| CA2807830C (en) * | 2010-08-24 | 2018-04-03 | Novartis Ag | Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy |
| MA37850A1 (fr) | 2012-08-24 | 2018-07-31 | Novartis Ag | Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale |
| US20160206597A1 (en) * | 2013-08-26 | 2016-07-21 | Toni Lynne Bransford | New Use |
-
2014
- 2014-08-26 WO PCT/IB2014/064074 patent/WO2015028941A1/en active Application Filing
- 2014-08-26 PL PL14761702T patent/PL3038654T3/pl unknown
- 2014-08-26 ES ES19202854T patent/ES2968541T3/es active Active
- 2014-08-26 HR HRP20240034TT patent/HRP20240034T1/hr unknown
- 2014-08-26 HU HUE19202854A patent/HUE064634T2/hu unknown
- 2014-08-26 LT LTEP14761702.1T patent/LT3038654T/lt unknown
- 2014-08-26 PT PT147617021T patent/PT3038654T/pt unknown
- 2014-08-26 JP JP2016537414A patent/JP6097888B2/ja active Active
- 2014-08-26 EP EP19202854.6A patent/EP3626270B1/en active Active
- 2014-08-26 RS RS20200047A patent/RS59816B1/sr unknown
- 2014-08-26 SI SI201432059T patent/SI3626270T1/sl unknown
- 2014-08-26 HU HUE14761702A patent/HUE047186T2/hu unknown
- 2014-08-26 FI FIEP19202854.6T patent/FI3626270T3/fi active
- 2014-08-26 PL PL19202854.6T patent/PL3626270T3/pl unknown
- 2014-08-26 LT LTEP19202854.6T patent/LT3626270T/lt unknown
- 2014-08-26 US US14/914,005 patent/US20160213646A1/en not_active Abandoned
- 2014-08-26 ES ES14761702T patent/ES2767084T3/es active Active
- 2014-08-26 EP EP14761702.1A patent/EP3038654B1/en active Active
- 2014-08-26 PT PT192028546T patent/PT3626270T/pt unknown
- 2014-08-26 SI SI201431464T patent/SI3038654T1/sl unknown
- 2014-08-26 RS RS20240031A patent/RS65037B1/sr unknown
- 2014-08-26 DK DK19202854.6T patent/DK3626270T3/da active
- 2014-08-26 DK DK14761702.1T patent/DK3038654T3/da active
- 2014-08-26 EP EP23202190.7A patent/EP4321157A3/en active Pending
-
2020
- 2020-01-16 HR HRP20200060TT patent/HRP20200060T1/hr unknown
- 2020-01-28 CY CY20201100075T patent/CY1122531T1/el unknown
- 2020-11-24 US US17/103,327 patent/US20210077461A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3626270T (pt) | 2024-01-11 |
| DK3626270T3 (da) | 2024-01-15 |
| CY1122531T1 (el) | 2021-01-27 |
| RS65037B1 (sr) | 2024-02-29 |
| HRP20240034T1 (hr) | 2024-03-29 |
| EP3038654A1 (en) | 2016-07-06 |
| LT3626270T (lt) | 2024-01-25 |
| JP6097888B2 (ja) | 2017-03-15 |
| FI3626270T3 (fi) | 2024-01-11 |
| EP3626270A1 (en) | 2020-03-25 |
| HUE047186T2 (hu) | 2020-04-28 |
| EP3626270B1 (en) | 2023-10-11 |
| JP2016528303A (ja) | 2016-09-15 |
| EP3038654B1 (en) | 2019-10-30 |
| PT3038654T (pt) | 2020-02-04 |
| SI3038654T1 (sl) | 2020-02-28 |
| ES2968541T3 (es) | 2024-05-10 |
| RS59816B1 (sr) | 2020-02-28 |
| EP4321157A3 (en) | 2024-05-15 |
| DK3038654T3 (da) | 2020-02-03 |
| US20160213646A1 (en) | 2016-07-28 |
| US20210077461A1 (en) | 2021-03-18 |
| ES2767084T3 (es) | 2020-06-16 |
| EP4321157A2 (en) | 2024-02-14 |
| WO2015028941A1 (en) | 2015-03-05 |
| SI3626270T1 (sl) | 2024-03-29 |
| HUE064634T2 (hu) | 2024-04-28 |
| LT3038654T (lt) | 2020-01-27 |
| PL3038654T3 (pl) | 2020-05-18 |
| PL3626270T3 (pl) | 2024-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200060T1 (hr) | Nova uporaba | |
| Chaudhary et al. | Uric acid-key ingredient in the recipe for cardiorenal metabolic syndrome | |
| HRP20230480T1 (hr) | Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca | |
| HRP20170848T1 (hr) | Kompozicije i metode za liječenje pluće hipertenzije | |
| HRP20171570T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
| TN2011000217A1 (en) | Pirfenidone treatment for patients with atypical liver fuction | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2015503593A5 (hr) | ||
| MX354249B (es) | Formas de dosificación farmacéuticas intranasales que comprenden naloxona. | |
| JP2010174019A5 (hr) | ||
| EA200970897A1 (ru) | Модифицированные лекарственные формы такролимуса | |
| JP2012193216A5 (hr) | ||
| RU2013136350A (ru) | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист | |
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2013516493A5 (hr) | ||
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| MX2013002418A (es) | Administracion de lorcaserina a individuos con daño renal. | |
| JP2012502103A5 (hr) | ||
| Krug et al. | Inhaled iloprost for the control of pulmonary hypertension | |
| RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина | |
| Tanios et al. | Emerging therapies for diabetic nephropathy patients: beyond blockade of the renin-angiotensin system | |
| TN2015000333A1 (en) | Identifying patient response to s1p receptor modulator administration | |
| JP2014513121A5 (hr) |